Skip to main content

Table 4 Changes from baseline in ADAS-cog for each quintile TTP488 concentration range over 18 months of treatment

From: Effect of TTP488 in patients with mild to moderate Alzheimer’s disease

Month Placebo 0.1-10.2 ng/mL 10.3-16.8 ng/mL 17.0-46.3 ng/mL 46.8-71.7 ng/mL 75-167 ng/mL
3 1.59 (0.43) 0.83 (0.75) 1.35 (0.74) 2.51 (0.77) 4.42 (0.84) 7.4 (0.94)
n = 129 n = 50 n = 51 n = 52 n = 47 n = 48
6 3.14 (0.54) 2.24 (0.85) 2.3 (0.87) 4 (0.88) 4.7 (0.82) 9.1 (1)
n = 115 n = 48 n = 49 n = 48 n = 37 n = 46
9 4.3 (0.7) 1.9 (0.9) 3 (0.93) 4.3(1.1) 5.1 (1.45) 8.4 (1.3)
n = 112 n = 39 n = 46 n = 42 n = 27 n = 40
12 6.4 (0.68) 3 (0.76) 5.6 (1.22) 6.7 (1.3) 7.4 (1.67) 9.3 (1.3)
n = 105 n = 32 n = 42 n = 37 n = 22 n = 31
15 9.9 (0.9) 6.8 (0.98) 6.9 (1.42) 8.1 (0.4) 9.3 (1.97) 10.1 (1.9)
n = 89 n = 30 n = 37 n = 30 n = 21 n = 24
18 11.9 (1.1) 8.7 (1.36) 8.1 (1.71) 10.1 (2) 10.1 (2.47) 11.3(1.8)
  n = 64 n = 25 n = 26 n = 25 n = 15 n = 19
  1. Data are reported as mean (sd), n.